A 20-peptide cancer vaccine (KRM-20) was safe and boosted immune responses in prostate cancer patients but did not improve PSA decline, progression-free, or overall survival versus placebo.
Immune response but no clinical benefitSignificant CTL (p=0.007) and IgG (p=0.018) responses, but 56.5% vs 53.8% PSA decline (not significant)
What the researchers found
KRM-20 vaccine elicited significant peptide-specific CTL and IgG immune responses (p=0.007, p=0.018) but did not improve clinical outcomes versus placebo when combined with docetaxel in CRPC.
Why it matters
Peptide cancer vaccines consistently generate immune responses but often fail to improve survival — understanding why is essential for improving immunotherapy for prostate and other cancers.
The numbers in context
25 vs 26 patients; PSA >50% decline: 56.5% vs 53.8% (NS); IgG p=0.018; CTL p=0.007; no PFS/OS difference; subgroup: benefit if lymphocytes >=26% or PSA <11.2
How the study worked
Double-blind, placebo-controlled, randomized phase II trial across 10 centers in Japan with 51 chemotherapy-naive CRPC patients receiving KRM-20 or placebo plus docetaxel/dexamethasone.
Who was studied
51 chemotherapy-naive CRPC patients from 10 Japanese medical centers
What this study cannot tell us
Small sample (n=51); phase II without OS primary endpoint; HLA restriction limits applicability; subgroup analyses are hypothesis-generating only; short follow-up.
How to read the evidence
Well-designed double-blind RCT, but small sample size and primary endpoint (PSA decline) was not met; subgroup findings are exploratory.
When this study was published
Published in 2020; the peptide vaccine field continues to evolve with combinations involving checkpoint inhibitors and neoantigen-based approaches.
The bigger picture
This trial illustrates the persistent gap between immunological response and clinical benefit in peptide cancer vaccines — a key challenge the field must solve for immunotherapy to succeed.
Questions still open
- Why do immune responses not translate to clinical benefit in peptide cancer vaccines?
- Would patient selection based on lymphocyte count or PSA improve outcomes in a larger trial?
- Could combining KRM-20 with checkpoint inhibitors instead of chemotherapy yield better results?
Common questions
Do peptide cancer vaccines work for prostate cancer?
Why do cancer vaccines boost immunity without improving survival?
Read the original research
Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial.
Cancer immunology, immunotherapy : CII, 69(5), 847-857
Citation
Noguchi, Masanori; Arai, Gaku; Egawa, Shin; Ohyama, Chikara; Naito, Seiji; Matsumoto, Kazumasa; Uemura, Hirotsugu; Nakagawa, Masayuki; Nasu, Yasutomo; Eto, Masatoshi; Suekane, Shigetaka; Sasada, Tetsuro; Shichijo, Shigeki; Yamada, Akira; Kakuma, Tatsuyuki; Itoh, Kyogo. (2020). Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial.. Cancer immunology, immunotherapy : CII, 69(5), 847-857. https://doi.org/10.1007/s00262-020-02498-8